N/A
N=54
Effect of Citrate Dialysate on Vascular Calcification
Vascular Calcification
Bottom Line
View on ClinicalTrials.gov: NCT04956120 ↗Enrolled (actual)
54
Serious AEs
0.0%
Results posted
May 2026
Primary outcome: Primary: Length of Calcified Artery Segments — 47; 9 millimeters (mm) per year
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Citrate Dialysate (Device); Standard Dialysate (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- Female
- Sponsor
- Emory University
- Primary completion
- Mar 2025
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Length of Calcified Artery Segments |
47; 9 | — |
| SECONDARY Serum Ionized Calcium (iCa) |
4.8; 4.8; 4.6; 4.9 | — |
| SECONDARY Serum Magnesium (Mg) |
2.3; 2.4; 2.0; 2.1 | — |
| SECONDARY Plasma Citrate |
134; 130; 383; 187 | — |
Summary
The goal of this study is to determine whether hemodialysis with citrate slows the progression of vascular calcification. Participants will be dialyzed with one of two standard dialysis solutions, one with and one without citrate, for 12 months and then switched to the other solution for 12 months. Vascular calcification will be measured on mammograms that will be performed at 6-month intervals and additional blood samples will be obtained at 6-month intervals.
Eligibility Criteria
Inclusion Criteria
- hemodialysis patients with BAC on mammograms
Exclusion Criteria
- current warfarin use
- severe hyperparathyroidism (likely to undergo parathyroidectomy in the next 2 years)
- difficulty controlling serum calcium (likely to require changes in dialysate calcium concentration in the next 2 years)
- life expectancy < 2 years
- prisoners
- inability to give consent
Data sourced from ClinicalTrials.gov (NCT04956120). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.